Physician profile
Daisy Ormseth
NPI 1811407901
$328.53
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $113 · 2022: $215.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $71.72 | 2021-2022 | |
| Alkermes, INC. | $43.11 | 2021-2022 | |
| Nestle Healthcare Nutrition INC. | $40.06 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $37.96 | 2022 | |
| Astrazeneca Pharmaceuticals Lp | $37.83 | 2022 | |
| Alnylam Pharmaceuticals INC. | $22.73 | 2022 | |
| Novo Nordisk INC | $21.89 | 2021 | |
| Glaxosmithkline, LLC. | $20.85 | 2022 | |
| Eisai INC. | $19.59 | 2021 | |
| Lilly USA, LLC | $12.79 | 2022 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daisy Ormseth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.